Shopping Cart
Remove All
Your shopping cart is currently empty
Stamulumab (MYO-029) is a high-affinity recombinant human antibody and myostatin neutralising antibody capable of increasing muscle mass in SCID mice. It may be employed in studying various muscular dystrophies, such as BMD, FSHD, and LGMD.

| Description | Stamulumab (MYO-029) is a high-affinity recombinant human antibody and myostatin neutralising antibody capable of increasing muscle mass in SCID mice. It may be employed in studying various muscular dystrophies, such as BMD, FSHD, and LGMD. |
| In vivo | Method: Stamulumab (1-10 mg/kg/week, 12 weeks) was administered intraperitoneally to female SCID mice to evaluate its efficacy. Results: Stamulumab dose-dependently increased skeletal muscle mass, with an Emax value of 23%-30% and a Cave50 range of 47-72 nM. [1] |
| Synonyms | MYO-029, MYO029 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 705287-60-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.